Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan.

摘要: Seventy to 40% of K-RAS wild type colorectal tumors does not seem benefit from treatment with antiepidermal growth factor receptor (anti-EGFR) monoclonal antibodies. Recent data suggested that in presence IGF-1 system, altered activation cancer cells may escape anti-EGFR mediated cell death. The interaction between expression and mutational analysis was tested verify the ability identify a subgroup patients more likely EGFR-targeted antibodies treatment. status assessed advanced receiving irinotecan/cetuximab. One hundred twelve were analyzed. negative 30 (27%) overexpressed remaining 82 cases (73%). In positive tumors, we observed progressive disease 9 (30%) 55 (67%) patients, respectively (p = 0.001). Median progression-free survival 7.5 mo showing 3 for expressing 0.002). Among showed partial response cetuximab-irinotecan 13 (65%) 11 (22%) cases, 10 3.2 cancers 0.02). proved be possible predictive resistance cancer. Combined represent an effective strategy better selection responding patients.